anticoagulant activity

抗凝血活性
  • 文章类型: Journal Article
    背景这项研究调查了来自无骨墨鱼Sepiellainermis内部骨骼的硫酸化壳聚糖的抗凝血特性。壳聚糖,一种生物聚合物,用于各种生物医学应用,包括抗凝。壳聚糖的硫酸化增强其生物活性,使其成为潜在的治疗剂。这项研究探索了硫酸化壳聚糖在防止血凝块形成中的功效,以提供一种新型的抗凝剂替代品。目的本研究旨在利用傅里叶变换红外光谱(FTIR)技术,合成并表征无骨墨鱼骨内硫酸化壳聚糖的抗凝血性能,场发射扫描电子显微镜(FESEM),和X射线衍射(XRD),并评估了从无骨墨鱼S.inermis内部骨提取的硫酸化壳聚糖的抗凝血性能。材料和方法从S.inermis标本的海绵体中提取甲壳素和壳聚糖,通过壳聚糖的硫酸化反应合成了硫酸化壳聚糖。硫酸化壳聚糖随后使用诸如活化部分凝血活酶时间(APTT)和凝血酶原时间(PT)的测试来评估其抗凝血性质。进行了特征调查,包括FTIR,FESEM,和XRD分析。结果这项研究的结果表明,使用S.inermis内部骨作为天然抗凝剂的非常规来源,可以与生物医学应用相结合。使用APTT和PT测量的抗凝血活性表明硫酸化壳聚糖是强抗凝剂。结论我们使用凝血酶和活化的部分凝血活酶时间检查了S.inermis提取物的抗凝血活性。我们的结果表明了提取的硫酸化壳聚糖的肝素样抗凝血作用,这表明它可能是一种很好的抗凝治疗方法。
    Background This study investigated the anticoagulant properties of sulfated chitosan derived from the internal bone of the spineless cuttlefish Sepiella inermis. Chitosan, a biopolymer, is used in various biomedical applications including anticoagulation. Sulfation of chitosan enhances its biological activity, making it a potential therapeutic agent. This study explored the efficacy of sulfated chitosan in preventing blood clot formation to provide a novel anticoagulant alternative. Objectives This study aimed to synthesize and characterize the anticoagulant properties of sulfated chitosan extracted from the internal bone of the spineless cuttlefish S. inermis using Fourier Transform Infrared Spectroscopy (FTIR), Field Emission Scanning Electron Microscopy (FESEM), and X-Ray Diffraction (XRD) and evaluate the anticoagulant properties of sulfated chitosan extracted from the internal bone of spineless cuttlefish S. inermis. Materials and methods Chitin and chitosan were extracted from the cuttlebone of a specimen of S. inermis, and sulfated chitosan was synthesized by sulfation of chitosan. Sulfated chitosan was subsequently used to evaluate its anticoagulant properties using tests such as activated partial thromboplastin time (APTT) and prothrombin time (PT). Characteristic investigations were conducted, including FTIR, FESEM, and XRD analyses. Results The results of this study suggested the possibility of using S. inermis internal bone as an unconventional source of natural anticoagulant that can be combined with biomedical applications. Anticoagulant activity measured using APTT and PT showed that sulfated chitosan was a strong anticoagulant. Conclusion We examined the anticoagulant activity of S. inermis extract using thrombin and activated partial thromboplastin times. Our results demonstrated the heparin-like anticoagulant action of the extracted sulfated chitosan, suggesting that it may be a great alternative anticoagulant treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    心血管疾病(CVD)影响生活质量或在最坏的情况下是致命的,造成了巨大的经济和社会负担。因此,迫切需要发明功能性产品或药物来改善患者健康并减轻和控制这些疾病。海洋生物活性肽减少和控制CVD。通过食用含有海洋生物肽的功能性食品,可以减轻触发CVD的许多诱发因素。因此,通过使用来自海洋来源的有效生物肽食品来改善CVD发病率已引起越来越多的兴趣和关注。这篇综述报道了来自各种海洋生物的生物活性肽的信息,专注于分离的过程,净化,和生物肽的鉴定,生物学特性,和促进心血管健康的功能性食品。越来越多的证据表明,海洋肽的生物活性和安全性显着影响其储存,净化,和处理。通过有效的安全测试方法,制定涉及功能性食品的进一步策略以治疗CVD是可行的。未来的工作应集中在生产高质量的海洋肽并将其应用于食品和药品行业。
    Cardiovascular diseases (CVDs) affect the quality of life or are fatal in the worst cases, resulting in a significant economic and social burden. Therefore, there is an urgent need to invent functional products or drugs for improving patient health and alleviating and controlling these diseases. Marine bioactive peptides reduce and control CVDs. Many of the predisposing factors triggering CVDs can be alleviated by consuming functional foods containing marine biopeptides. Therefore, improving CVD incidence through the use of effective biopeptide foods from marine sources has attracted increasing interest and attention. This review reports information on bioactive peptides derived from various marine organisms, focusing on the process of the separation, purification, and identification of biological peptides, biological characteristics, and functional food for promoting cardiovascular health. Increasing evidence shows that the bioactivity and safety of marine peptides significantly impact their storage, purification, and processing. It is feasible to develop further strategies involving functional foods to treat CVDs through effective safety testing methods. Future work should focus on producing high-quality marine peptides and applying them in the food and drug industry.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    由于美妙的味道,丰富的营养和生物功能,Caulerpa属中的许多海洋绿藻最近被开发为绿色鱼子酱的候选物。从绿藻泡菜中获得了一种新型的水溶性硫酸化木乳甘露聚糖CO-0-1。CO-0-1主要由甘露糖(Man)组成,半乳糖(Gal),和木糖(Xyl)的比例为4.4:4.0:1.4,分子量为470kDa,硫酸盐含量为12.78%。硫酸化的木聚糖在骨架上具有→4)-β-D-Manp-(1→和→2)-β-D-Manp-(1→作为主链和O-3位置的分支。侧链包含→3)-β-D-Galp-(1→和次要→2)-β-D-Xylp(1→。硫酸酯基团仅分布在侧链和→3的O-6位置)-β-D-Galp-((1→2)-β-D-Xylp的1→和O-4位置。抗凝血活性表明CO-0-1表现出内在抗凝血和特异性抗凝血酶活性。调查扩大了绿藻的利用和开发场景和范围。
    Due to wonderful taste, rich nutrition and biological functions, many marine green algae in the genus Caulerpa have been recently developed as candidates for green caviar. A novel water-soluble sulfated xylogalactomannan CO-0-1 was obtained from the green algae Caulerpa okamurae. CO-0-1 was mainly composed of mannose (Man), galactose (Gal), and xylose (Xyl) at the ratio of 4.4:4.0:1.4 with the molecular weight at 470 kDa and the sulfate content at 12.78 %. The sulfated xylogalactomannan had Man at the backbone with →4)-β-D-Manp-(1→ and →2)-β-D-Manp-(1→ as the main chain and branches at O-3 position. The side chains contained →3)-β-D-Galp-(1→ and minor →2)-β-D-Xylp(1→. The sulfate groups only distributed at the side chains and at O-6 position of →3)-β-D-Galp-(1→ and O-4 position of (1→2)-β-D-Xylp. The anticoagulant activity indicated that CO-0-1 displayed intrinsic anticoagulant and specific anti-thrombin activities. The investigation expanded the utilization and development scene and scope of the green algae Caulerpa okamurae.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    通过鸡腿草的液体发酵生产了一种新型的纤溶酶。通过疏水相互作用从培养上清液中纯化酶,凝胶过滤,和离子交换色谱法。它被纯化了241.02倍,比活度为3619U/mg,终收率为10.02%。SDS-PAGE分析证实了酶的纯度,显示分子量为19.5kDa的单个条带。纯化酶N端的前9个氨基酸是A-T-Y-T-G-G-S-Q-T。该酶在42°C的温度和pH7.6下表现出最佳活性。Zn2+显著提高了其活性,K+,Ca2+,Mn2+,和Mg2+同时被Fe2+抑制,Fe3+,Al2+,Ba2+乙二胺四乙酸(EDTA)完全抑制酶的活性,苯甲基磺酰氟(PMSF)和大豆胰蛋白酶抑制剂(SBTI)也呈剂量依赖性抑制。然而,抑制剂如N-α-甲苯磺酰基-L-苯丙氨酸氯甲基酮(TPCK),抑肽酶,和胃蛋白酶抑制素没有显著影响其活性,表明该酶是丝氨酸样金属蛋白酶。该酶既充当纤溶酶样纤溶酶,又充当纤溶酶原激活剂,它还表现出水解纤维蛋白原和纤维蛋白的能力。体外,它证明了溶解血凝块的能力,并具有抗凝血特性。此外,发现该酶延长了活化的部分凝血活酶时间(APTT),凝血酶原时间(PT),和凝血酶时间(TT),并降低纤维蛋白原(FIB)和凝血酶原活性(PA)的水平。基于这些研究,该酶有很大的潜力被开发为预防和治疗血栓性疾病的天然药物。
    A novel fibrinolytic enzyme was produced by the liquid fermentation of Coprinus comatus. The enzyme was purified from the culture supernatant by hydrophobic interactions, gel filtration, and ion exchange chromatographies. It was purified by 241.02-fold, with a specific activity of 3619 U/mg and a final yield of 10.02%. SDS-PAGE analysis confirmed the purity of the enzyme, showing a single band with a molecular weight of 19.5 kDa. The first nine amino acids of the N-terminal of the purified enzyme were A-T-Y-T-G-G-S-Q-T. The enzyme exhibited optimal activity at a temperature of 42 °C and pH 7.6. Its activity was significantly improved by Zn2+, K+, Ca2+, Mn2+, and Mg2+ while being inhibited by Fe2+, Fe3+, Al2+, and Ba2+. The activity of the enzyme was completely inhibited by ethylenediamine tetraacetic acid (EDTA), and it was also dose-dependently inhibited by phenylmethylsulfonyl fluoride (PMSF) and soy trypsin inhibitor (SBTI). However, inhibitors such as N-α-tosyl-L-phenylalanine chloromethyl ketone (TPCK), aprotinin, and pepstatin did not significantly affect its activity, suggesting that the enzyme was a serine-like metalloproteinase. The enzyme acted as both a plasmin-like fibrinolytic enzyme and a plasminogen activator, and it also exhibited the capability to hydrolyze fibrinogen and fibrin. In vitro, it demonstrated the ability to dissolve blood clots and exhibit anticoagulant properties. Furthermore, it was found that the enzyme prolonged activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT), and reduced the levels of fibrinogen (FIB) and prothrombin activity (PA). Based on these studies, the enzyme has great potential to be developed as a natural agent for the prevention and treatment of thrombotic diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    本文致力于确定四种Filipendula属提取物中酚类化合物的组成,以建立多酚组成与生物学效应之间的联系。化学分析表明,所研究的提取物的组成取决于植物种类及其部分(叶或花)以及所用的提取剂。所有四种Filipendula都是酚类化合物的丰富来源,并含有可水解的单宁,缩合单宁,酚酸及其衍生物,和类黄酮.这些活动包括对制造具有Filipendula植物成分的功能食品最重要的数据:通过凝血酶原和活化的部分凝血活酶时间对血液凝固的影响,以及消化酶(胰腺淀粉酶和脂肪酶)的活性。已经确定植物物种,他们的部分,和提取方法有助于有意义的生物活性。最突出的结果如下:植物器官决定了淀粉酶或脂肪酶的选择性抑制;因此,F.camtschatica和F.stepposa的抗凝血活性有望用于与一般代谢紊乱相关的促进健康的食品配方。
    This current article was dedicated to the determination of the composition of phenolic compounds in extracts of four species of the genus Filipendula in order to establish a connection between the composition of polyphenols and biological effects. A chemical analysis revealed that the composition of the extracts studied depended both on the plant species and its part (leaf or flower) and on the extractant used. All four species of Filipendula were rich sources of phenolic compounds and contained hydrolyzable tannins, condensed tannins, phenolic acids and their derivatives, and flavonoids. The activities included data on those that are most important for creating functional foods with Filipendula plant components: the influence on blood coagulation measured by prothrombin and activated partial thromboplastin time, and on the activity of the digestive enzymes (pancreatic amylase and lipase). It was established that plant species, their parts, and extraction methods contribute meaningfully to biological activity. The most prominent result is as follows: the plant organ determines the selective inhibition of either amylase or lipase; thus, the anticoagulant activities of F. camtschatica and F. stepposa hold promise for health-promoting food formulations associated with general metabolic disorders.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    海洋绿藻产生结构多样、生物活性广泛的硫酸化多糖。这项研究旨在通过对巴西盖拉利亚的硫酸化异鼠南(Gb1)进行化学修饰以改善或新的生物学功能,从而增强其生物技术潜力。使用受控的史密斯降解(GBS)和与3-氯丙胺的O-烷基化,我们合成了部分水溶性胺衍生物。GBS修饰增加硫酸盐基团(29.3至37.5%)和α-L-鼠李糖单位(69.9至81.2mol%),减少木糖和葡萄糖,与GB1相比。主链主要以3-和2-连接的α-L-鼠李糖基和2,3-连接的α-L-鼠李糖基单元为分支点。红外和NMR分析证实羟基被氨基烷基取代。改性化合物,GBS-AHC和GBS-AHK,表现出改变的抗凝血特性。GBS-AHC在APTT分析中显示出降低的有效性,而GBS-AHK维持与Gb1和GBS相似的抗凝活性水平。与GBS-AHK相比,GBS-AHC中氮含量和N-烷基化的增加可能解释了它们的结构差异。提出的化学修饰没有增强其抗凝血活性,可能是由于引入了氨基和聚合物的正电荷。这一特征为研究这些多糖在各种生物应用中的潜力提供了新的机会。如抗菌和抗肿瘤活性。
    Marine green algae produce sulfated polysaccharides with diverse structures and a wide range of biological activities. This study aimed to enhance the biotechnological potential of sulfated heterorhamnan (Gb1) from Gayralia brasiliensis by chemically modifying it for improved or new biological functions. Using controlled Smith Degradation (GBS) and O-alkylation with 3-chloropropylamine, we synthesized partially water-soluble amine derivatives. GBS modification increase sulfate groups (29.3 to 37.5 %) and α-l-rhamnose units (69.9 to 81.2 mol%), reducing xylose and glucose, compared to Gb1. The backbone featured predominantly 3- and 2-linked α-l-rhamnosyl and 2,3- linked α-l-rhamnosyl units as branching points. Infrared and NMR analyses confirmed the substitution of hydroxyl groups with aminoalkyl groups. The modified compounds, GBS-AHCs and GBS-AHK, exhibited altered anticoagulant properties. GBS-AHCs showed reduced effectiveness in the APTT assay, while GBS-AHK maintained a similar anticoagulant activity level to Gb1 and GBS. Increased nitrogen content and N-alkylation in GBS-AHCs compared to GBS-AHK may explain their structural differences. The chemical modification proposed did not enhance its anticoagulant activity, possibly due to the introduction of amino groups and a positive charge to the polymer. This characteristic presents new opportunities for investigating the potential of these polysaccharides in various biological applications, such as antimicrobial and antitumoral activities.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    血栓栓塞是心血管疾病的罪魁祸首,导致全球死亡率最高。抗凝成为控制血栓形成的主要方法。值得注意的是,硫酸化多糖表现出良好的抗凝血功效,副作用减少。本文就硫酸多糖的结构-抗凝血活性关系及其作用机制作一综述。结论氯磺酸-吡啶法是合成硫酸多糖的优选技术。硫酸多糖的抗凝血活性与硫酸基团的取代位点有关,替代程度,分子量,主侧链结构,和糖苷键构象。此外,硫酸多糖通过各种途径发挥抗凝血活性,包括抑制凝血因子,抗凝血酶III和肝素辅因子II的激活,抗血小板聚集,和促进纤溶系统。
    Thromboembolism is the culprit of cardiovascular diseases, leading to the highest global mortality rate. Anticoagulation emerges as the primary approach for managing thrombotic conditions. Notably, sulfated polysaccharides exhibit favorable anticoagulant efficacy with reduced side effects. This review focuses on the structure-anticoagulant activity relationship of sulfated polysaccharides and the underlying action mechanisms. It is concluded that chlorosulfonicacid-pyridine method serves as the preferred technique to synthesize sulfated polysaccharides. The anticoagulant activity of sulfated polysaccharides is linked to the substitution site of sulfate groups, degree of substitution, molecular weight, main side chain structure, and glycosidic bond conformation. Moreover, sulfated polysaccharides exert anticoagulant activity via various pathways, including the inhibition of blood coagulation factors, activation of antithrombin III and heparin cofactor II, antiplatelet aggregation, and promotion of the fibrinolytic system.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    血栓栓塞疾病是发达国家最常见的死亡原因。抗凝治疗是首选的治疗方法,类肝素和华法林是最常用的药物。从海洋生物中提取的硫酸多糖已被证明是有效的替代品,通过抑制凝血级联反应中的一些因素来阻断血栓形成。在这项研究中,通过阴离子交换色谱纯化了来自海绵状沙棘的四个酸性聚糖级分,并通过APTT和PT测定研究了它们的抗凝血特性,并与标准糖胺聚糖和霍耳硫酸多糖进行了比较。此外,通过组织学分析评估了它们的地形定位,并在人成纤维细胞系上测试了它们的细胞相容性。观察到酸性聚糖的量与对内源性和外源性凝血途径的抑制作用之间呈正相关。高电荷部分显示出最有效的抗凝血活性,几乎占含己糖醛酸盐多糖总量的一半(约40%)。其初步结构表征,通过红外光谱和核磁共振,建议它可能由岩藻糖基化的硫酸软骨素组成,其独特的结构可能是本文首次报道的抗凝血活性的原因。
    Thromboembolic conditions are the most common cause of death in developed countries. Anticoagulant therapy is the treatment of choice, and heparinoids and warfarin are the most adopted drugs. Sulphated polysaccharides extracted from marine organisms have been demonstrated to be effective alternatives, blocking thrombus formation by inhibiting some factors involved in the coagulation cascade. In this study, four acidic glycan fractions from the marine sponge Sarcotragus spinosulus were purified by anion-exchange chromatography, and their anticoagulant properties were investigated through APTT and PT assays and compared with both standard glycosaminoglycans and holothurian sulphated polysaccharides. Moreover, their topographic localization was assessed through histological analysis, and their cytocompatibility was tested on a human fibroblast cell line. A positive correlation between the amount of acid glycans and the inhibitory effect towards both the intrinsic and extrinsic coagulation pathways was observed. The most effective anticoagulant activity was shown by a highly charged fraction, which accounted for almost half (about 40%) of the total hexuronate-containing polysaccharides. Its preliminary structural characterization, performed through infrared spectroscopy and nuclear magnetic resonance, suggested that it may consist of a fucosylated chondroitin sulphate, whose unique structure may be responsible for the anticoagulant activity reported herein for the first time.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:当归四尼汤(DGSN)是中医临床实践中的经典方剂。DGSN汤常用于缓解伤寒论(《伤寒论》)记载的寒凝血瘀症状,治疗雷诺氏病,痛经,关节炎,偏头痛在中医诊所。越来越多的证据表明,这种疾病与微循环障碍有关。然而,负责治疗的DGSN汤的抗凝活性和潜在机制尚不清楚。
    目的:对DGSN汤的指纹图谱及体内外抗凝活性进行评价,以加强方剂的质量控制和活性研究。
    方法:采用高效液相色谱法对DGSN汤剂的化学成分进行分析,并采用《中药色谱指纹图谱相似度评价软件(2012年版)》进行指纹图谱相似度评价。通过测量四种凝血因子(PT,TT,APTT,FIB)体外。建立普纳替尼诱导的斑马鱼血栓形成模型,评价其改善体内微血管血流动力学的活性。采用定量实时聚合酶链反应(q-PCR)比较凝血因子II(FII)RNA表达水平的变化,VII(FVII),斑马鱼血栓形成模型的IX(FIX)和X(FX)。
    结果:建立了DGSN汤剂的指纹图谱相似性评价方法。结果表明,18个样品具有较高的相似性(S1-S18>0.878)。药效学结果表明,DGSN汤可以延长PT,TT和APTT,并降低体外FIB含量。同时,在低剂量(500μgmL-1)下,它显着增强了体内心输出量和血流速度。q-PCR数据表明,DGSN汤(500μgmL-1)可以下调FII的RNA表达,FVII,FIX和FX。有趣的是,FII有双向调节,FIX和FX在一定浓度范围内。总的来说,DGSN汤可显著改善血流动力学,下调凝血因子,结果在体外-体内是一致的。
    结论:指纹图谱研究为提高DGSN汤的质量控制提供了新的视角。DGSN汤通过同时调节多种凝血因子而具有抗凝活性。因此,具有开发成为新型抗凝药物原料的潜力。
    BACKGROUND: Dang-Gui-Si-Ni (DGSN) decoction is a classic prescription in the clinical practice of traditional Chinese Medicine (TCM). DGSN decoction is often used to relieve symptoms of cold coagulation and blood stasis recorded by Treatise on Febrile Diseases (Shang Han Lun) and treat Raynaud\'s disease, dysmenorrhea, arthritis, migraine in TCM clinic. Accumulated evidences have suggested that this diseases are related to microcirculation disturbance. However, the anticoagulant activity and underlying mechanisms of DGSN decoction responsible for the therapeutic not well understood.
    OBJECTIVE: The fingerprint and anticoagulant activity in vivo-in vitro of DGSN decoction were evaluated to strengthen the quality control and activity study of formulas.
    METHODS: The chemical components of DGSN decoction were analyzed by HPLC and its fingerprint similarity were evaluated by \"Chinese Medicine Chromatographic Fingerprint Similarity Evaluation Software (2012 Edition)\". The anticoagulant activity of DGSN decoction was assessed by measuring four coagulation factors (PT, TT, APTT, FIB) in vitro. Zebrafish thrombosis model induced by punatinib was established to evaluate the activity of improving microvascular hemodynamics in vivo. Quantitative real-time polymerase chain reaction (q-PCR) were adopted to compare the changes in the RNA expression levels of coagulation factor II (FII), VII (FVII), IX (FIX) and X (FX) in zebrafish thrombosis model.
    RESULTS: The fingerprint similarity evaluation method of DGSN decoction was established. The results showed that 18 samples had higher similarity (S1-S18 > 0.878). Pharmacodynamic results showed that DGSN decoction could extend PT, TT and APTT, and reduce FIB content in vitro. Meanwhile, it markedly enhanced the cardiac output and blood flow velocity at low dosage (500 μg mL-1) in vivo. q-PCR data demonstrated that DGSN decoction (500 μg mL-1) could downregulate the RNA expression of FII, FVII, FIX and FX. Interestingly, there were a bidirectional regulation of FII, FIX and FX in a certain concentration range. In general, DGSN decoction can significantly improve hemodynamics and downregulate coagulation factors, and the results were consistent both in vitro - in vivo.
    CONCLUSIONS: The fingerprint study provide a new perspective for improving the quality control of DGSN decoction. DGSN decoction possess anticoagulant activity by regulating multiple coagulation factors simultaneously. Thus, it has the potential to develop into the novel raw material of anticoagulant drugs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    来自海洋动物的具有独特结构的糖胺聚糖(GAG)显示出有趣的药理活性和可忽略的生物风险,为我们探索更安全的代理商提供更多选择。游泳膀胱是一种滋补食品和民间药物,及其GAG显示出良好的抗凝血活性。在这项研究中,两个GAG,CMG-1.0和GMG-1.0是从Cynoscionmicrolepidotus和Gadusmorhua的膀胱中提取和分离的。物理化学性质,精确的结构特征,首次测定了这些GAG的抗凝血活性。CMG-1.0和GMG-1.0的分析结果表明,它们是硫酸软骨素(CS)/硫酸皮肤素(DS)杂链,分子量分别为109.3kDa和123.1kDa,分别。它们主要由-{IdoA-α1,3-GalNAc4S-β1,4-}-(DS-A)的重复二糖单元组成。-{IdoA2S-α1,3-GalNAc4S-β1,4-}的DS-B二糖单元也存在于CMG-1.0和GMG-1.0中。与GMG-1.0相比,CMG-1.0具有较高比例的CS-O二糖单元-{-GlcA-β1,3-GalNAc-β1,4-},但较低比例的CS-E二糖单元-{-GlcA-β1,3-GalNAc4S6S-β1,4-}。GAG的二糖组成以物种特异性方式变化。抗凝活性测定显示CMG-1.0和GMG-1.0均具有有效的抗凝活性,能明显延长活化部分凝血活酶时间。GMG-1.0还可以延长凝血酶时间。CMG-1.0没有显示内在的tenase抑制活性,而GMG-1.0可以明显抑制内在tenase,EC50为58nM。它们显著不同的抗凝血活性可能是由于它们不同的二糖结构单元和比例。这些发现表明,这两种海洋生物的鱼类加工的游泳膀胱副产品可用作抗凝剂的来源。
    Glycosaminoglycans (GAGs) with unique structures from marine animals show intriguing pharmacological activities and negligible biological risks, providing more options for us to explore safer agents. The swim bladder is a tonic food and folk medicine, and its GAGs show good anticoagulant activity. In this study, two GAGs, CMG-1.0 and GMG-1.0, were extracted and isolated from the swim bladder of Cynoscion microlepidotus and Gadus morhua. The physicochemical properties, precise structural characteristics, and anticoagulant activities of these GAGs were determined for the first time. The analysis results of the CMG-1.0 and GMG-1.0 showed that they were chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chains with molecular weights of 109.3 kDa and 123.1 kDa, respectively. They were mainly composed of the repeating disaccharide unit of -{IdoA-α1,3-GalNAc4S-β1,4-}- (DS-A). The DS-B disaccharide unit of -{IdoA2S-α1,3-GalNAc4S-β1,4-}- also existed in both CMG-1.0 and GMG-1.0. CMG-1.0 had a higher proportion of CS-O disaccharide unit -{-GlcA-β1,3-GalNAc-β1,4-}- but a lower proportion of CS-E disaccharide unit -{-GlcA-β1,3-GalNAc4S6S-β1,4-}- than GMG-1.0. The disaccharide compositions of the GAGs varied in a species-specific manner. Anticoagulant activity assay revealed that both CMG-1.0 and GMG-1.0 had potent anticoagulant activity, which can significantly prolong activated partial thromboplastin time. GMG-1.0 also can prolong the thrombin time. CMG-1.0 showed no intrinsic tenase inhibition activity, while GMG-1.0 can obviously inhibit intrinsic tenase with EC50 of 58 nM. Their significantly different anticoagulant activities may be due to their different disaccharide structural units and proportions. These findings suggested that swim bladder by-products of fish processing of these two marine organisms may be used as a source of anticoagulants.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号